CTEP is a selective and potent negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). It has been primarily investigated for its potential in treating neurological and psychiatric disorders. Due to its ability to cross the blood-brain barrier and provide sustained receptor inhibition, CTEP has been used in preclinical research to study conditions such as Fragile X syndrome, autism spectrum disorders, Parkinson’s disease, and levodopa-induced dyskinesia. It has also shown promise in models of anxiety, depression, and drug addiction, particularly in reducing cocaine-seeking behavior. Its long half-life makes it suitable for chronic dosing studies in animal models, supporting its use as a research tool to explore mGluR5-related pathways and therapeutic interventions.